EMA begins internal reorganization

Starting Thursday, EMA began a transition to a new internal organizational structure for regulating human medicines. The new structure will comprise four divisions: support for industry's R&D phase; medicine evaluation and lifecycle management; procedure management and business data; and inspections and pharmacovigilance. Previously, EMA's human medicines organization included two units: Human Medicines Development and Evaluation; and Patient Health Protection. EMA began a review of its organizational structure in December (see BioCentury Extra, Dec. 19, 2012). ...